Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

will be available through Sept. 14, 2007.

About TRU-015 and SMIP(TM) Therapeutics

Trubion and Wyeth Pharmaceuticals are developing small modular immunopharmaceutical (SMIP(TM)) therapeutics directed to CD20, an antigen present on B cells. In addition to the ongoing development of TRU-015 for RA, investigational new drug applications have been filed for TRU-015 for systemic lupus erythematosus and non-Hodgkin's lymphoma. Trubion's SMIP drug candidates represent a novel class of immunotherapeutics that the company believes possess enhanced drug properties over monoclonal and recombinant antibodies. SMIP product candidates are novel single-chain polypeptide proteins designed using Trubion's custom drug assembly technology. Trubion's current product candidates bind to specific antigen targets on a cell's surface that have been clinically validated as important in disease management either by existing products or by potential products in clinical trials.

About Rheumatoid Arthritis

RA is a chronic disease, mainly characterized by inflammation of the lining, or synovium, of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. According to Datamonitor, RA is estimated to affect approximately 4.3 million people in the United States, Japan and Europe. In 2006, total reported worldwide sales of protein therapeutics used for the treatment of RA were greater than $9.5 billion.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatmen
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... Therapeutics (Nasdaq: NKTR ) today reported its financial ... Cash and investments in marketable securities at June ... at March 31, 2014."The second half of 2014 will be ... significant milestones for a number of our late-stage clinical programs," ... Nektar. "The first of these is the potential US and ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9
... and Oncomine Concepts Map Integral in Expression and Association ... ... Building on an earlier study,that used Oncomine(TM) to identify ETS-fusion proteins in ... of,four additional classes of ETS rearrangements in prostate cancer, each of,which activates ...
... Va., Aug. 2 The American Society,for Therapeutic ... for Lymphoma, a short treatment guide to assist ... outlines the major,differences between the diseases, explains radiation ... before, during and after radiation,therapy. "A cancer ...
Cached Medicine Technology:Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications 2
(Date:8/1/2014)... Market Publishers Ltd announces that ... added to its catalogue. , Pharmaceutical ... Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics ... include, among others, increasing ageing population, rising incomes ... the pharma market in India is anticipated to ...
(Date:8/1/2014)... Patients with the progressive, deadly respiratory ailment known as ... to battle the disease, the U.S. Food and Drug ... new treatment, an inhaled spray called Striverdi Respimat (olodaterol) ... which is often linked to smoking, involves multiple lung ... Patients with COPD may experience a number of symptoms, ...
(Date:8/1/2014)... North America Endpoint Security Market report defines and segments ... analysis and forecast of revenue. This market is estimated ... $4.77 billion by 2019, at a CAGR of 6.2% ... of the North America Endpoint Security Market report to ... also provides a glimpse of the segmentation in market, ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... in digestion help keep the intestinal lining intact. The ... could yield new therapies for inflammatory bowel disease (IBD) ... research involved the intestinal microbiome, which contains some 100 ... or preventing disease is a major emerging field of ...
(Date:8/1/2014)... By Kathleen Doheny ... (HealthDay News) -- Birth control pills containing high doses ... the risk of breast cancer in women under 50, ... oral contraceptive formulations," explained lead researcher Elisabeth Beaber, a ... in Seattle. "Some of these formulations increase breast cancer ...
Breaking Medicine News(10 mins):Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:FDA Approves New Treatment for People With COPD 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... women around the world, including an estimated 50,000 in ... by Georgetown University Medical Centers Institute for Reproductive Health. ... CycleBeads a visual aid developed by the Institute to ... pregnancy. , Now CycleBeads are available in a ...
... Dermatologist says ,I am revolted by it;, Petitions ... Feb. 4 A group of,dermatologists, including Dr. ... of Dermatopathology in New York City, has called ... program a,"shocking conflict of interest." The AAD agreed ...
... Feb. 4 Sage Software today announced that,Navarre Avenue ... by,Sage for the practice,s Electronic Health Records needs., ... this,year, according to Joni Tarver, Office Manager of Navarre ... practice,s rapid growth and,lack of chart space prompted the ...
... use, WASHINGTON, Feb. 4 The use ... the levels of phthalates,found in the babies, urine, ... researchers published today in Pediatrics Journal., In ... malformations of the male reproductive tract. Several human ...
... the world of organ donation, it has been common practice ... donor supply and lower survival rates. ... successful lung transplant at 65, are proving that perhaps age ... UCLA Medical Center study shows that select patients age 65 ...
... for Sharps Disposal by Mail System(R) and other products reach $3.8 ... by growth in pharmaceutical and hospitality markets - Strong operating leverage ... $400 thousand also expected in third ... quarter fiscal 2008, - ...
Cached Medicine News:Health News:CycleBeads help women manage their fertility 2Health News:American Academy of Dermatology Caught in Pay-for-Play Scandal 2Health News:Ohio Obstetrics and Gynecology Practice Selects Intergy EHR by Sage Electronic Health Record System 2Health News:Chemical Linked to Reproductive Harm Is Getting Into Babies From Shampoo, Lotion and Powder, New Study Suggests 2Health News:Study finds good outcomes for older lung transplant patients 2Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 2Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 3Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 4Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 5Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 6Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 7Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 8Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 9Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 10Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 11Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 12
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Multi-Tier Shaker...
... The Thermo Labsystems Wellmix is a ... and time settings. The shaking speed is ... shaking frequency, high speed and a small ... assays. The shaking time is quick and ...
Medicine Products: